Unum Group, an insurance company specializing in health, disability, and benefits coverage, has experienced a temporary setback after disappointing Q4 2025 earnings, with stock down 6% year-to-date. However, the article identifies three catalysts that could drive recovery: (1) executing a plan to return 100% of free cash flow to shareholders through buybacks and dividends, (2) achieving premium growth above the guided 4-7% range, and (3) stabilizing disability benefit ratios back to the 62-64% range to restore underwriting profitability.

Unum Group reported Q2 2025 earnings of $2.07 per share, missing analyst estimates. Revenue grew to $3.36 billion, but the company experienced challenges in claims costs, customer retention, and new business sales across its insurance segments.

Five U.S. stocks have recently increased their dividends, with analysts seeing potential for price appreciation and attractive total return potential over the next 12 months.

Globe Life Inc.'s first-quarter 2025 net operating income missed estimates, but premiums and underwriting income improved. The company's results were impacted by lower investment income and higher expenses.

Unum is a strong dividend stock with a 2.68% dividend yield, which is higher than the industry and S&P 500 averages. The company has increased its dividend by an average of 7.59% annually over the last 5 years, and its payout ratio is low at 18%, indicating potential for future dividend growth.

Unum (UNM) is an attractive dividend play with a strong Zacks Rank of #2 (Buy). The company has seen a 20.9% increase in its annualized dividend over the past year and has a dividend yield of 3.09%, higher than the industry and S&P 500 averages. Unum's earnings are expected to grow 10.44% this fiscal year, making it a compelling investment opportunity.

The cancer insurance market is expected to grow strongly in the coming years, driven by factors such as rising cancer incidence rates, medical inflation, and heightened awareness. Key trends include innovative product developments, customizable policies, and integration with health plans. The increasing number of cancer cases is a major driver for the market's growth.

The Accident and Health Insurance industry is expected to benefit from increased underwriting exposure and adoption of technology, despite ongoing pricing pressure and potential rise in claims frequency. Aflac, Unum Group, and Trupanion are highlighted as companies that should continue to perform well in this environment.

Unum Group has agreed to divest its Medical Stop Loss business to Amynta Group, a leading insurance services provider. This move will help Unum focus on its strategic growth priorities. The addition of Unum's Medical Stop Loss business will enhance Amynta Group's product portfolio and help it serve clients better.

Favorable sales trends and risk experience, strong persistency, an improving rate environment and a solid capital position poise Unum (UNM) well.

Ratings for Unum Gr (NYSE:UNM) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 2 1 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.2, with a high estimate of $66.00 and a low estimate of $52.00. Marking an increase of 4.59%, the current average surpasses the previous average price target of $56.60. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive Unum Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Thomas Gallagher Evercore ISI Group Raises In-Line $58.00 $56.00 Mark Hughes Truist Securities Raises Buy $62.00 $57.00 Nigel Dally Morgan Stanley Raises Equal-Weight $52.00 $50.00 Elyse Greenspan Wells Fargo Raises Overweight $66.00 $64.00 Jimmy Bhullar JP Morgan Raises Overweight $58.00 $56.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Unum Gr. This information provides a snapshot of how analysts perceive the current state ...Full story available on Benzinga.com

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Unum (UNM) have what it takes? Let's find out.